Backed by influencial names in the life sciences industry, Latent Labs offers an AI platform to accelerate and improve drug ...

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for ...

Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...

The company is developing generative AI methods to design proteins from scratch, with applications in drug discovery and ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

Nature Medicine has been chronicling advances in medical technology and health care. To mark the journal’s 30th anniversary, each month ...

A team of scientists has developed a groundbreaking approach using specially designed peptides to improve drug formulations. This innovative method significantly enhances anti-tumor efficacy.

United Kingdom, 15 th January 2025: Oxford Drug Design, the Oxford-based AI drug discovery company, has today announced additional in vivo validation for its first-in-class approach against cancer as ...

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its first-in-class cancer treatment approach. The company is developing novel treatments ...

Oxford Drug Design Ltd. has announced additional in vivo validation for its novel approach against cancer. The innovative approach, using generative AI capabilities, is based on the novel target ...